US Patent 7,659,256: Scope, Claims, Expiration, Litigation, and Qsymia Patent Landscape

US Patent 7,659,256 covered methods of treating obesity and promoting weight loss with phentermine combined with a sulfamate anticonvulsant, principally topiramate. Its central commercial application was the fixed-dose and separately administered phentermine/topiramate regimen marketed as Qsymia by VIVUS. The patent issued on February 9, 2010, and its 20-year patent term expired on October 28, 2022, subject to any applicable patent-term adjustment or pediatric extension reflected in the official records. The core claims are no longer a current US patent barrier to generic combination products.

The patent’s strongest historical coverage was directed to the combination of phentermine and topiramate, including simultaneous administration, separate administration, morning phentermine dosing, later-day topiramate dosing, dosage titration, oral delivery, and immediate-release or controlled-release dosage forms. Claim 29 separately claimed a pharmaceutical composition containing topiramate and phentermine.

What does US Patent 7,659,256 protect?

The patent protects two principal categories:

A treatment method using phentermine and a sulfamate anticonvulsant to effect weight loss.
A pharmaceutical composition containing topiramate and phentermine.

The patent is associated with the Qsymia development program. Qsymia contains immediate-release phentermine and extended-release topiramate in a single oral capsule. The approved strengths are substantially narrower than the full dosage ranges recited in the patent claims.

Protection category	Relevant claims	Main limitation
Combination weight-loss method	1	Phentermine plus a sulfamate anticonvulsant
Topiramate-specific method	2	Phentermine plus topiramate
Phentermine dose	3, 7	5-60 mg daily, or specifically 15 mg daily
Topiramate dose	4-6, 8-10	50-1,500 mg daily, with narrower claims below 400 mg
Patient population	11-14	Overweight, obese, non-overweight, or a weight-related condition
Simultaneous administration	15-16, 20-21	Same time, including a single formulation
Separate administration	17-18, 22-24	Different times, including morning phentermine and later topiramate
Titration	25	Gradual increase to a maintenance dose
Release profile	26-27	Immediate-release phentermine; immediate- or controlled-release topiramate
Oral administration	28	Oral delivery
Composition	29	Topiramate plus phentermine

How broad is claim 1 of US Patent 7,659,256?

Claim 1 is a combination-treatment claim with a broad chemical genus. It requires:

A subject;
Administration of phentermine;
Administration of a therapeutically effective amount of an anticonvulsant sulfamate derivative;
The derivative must satisfy the structural formula defined in the claim; and
The combination must effect weight loss.

The claim is broader than a topiramate-only claim because it covers compounds within the specified sulfamate derivative genus. Claim 2 narrows the genus to topiramate.

The claim does not require:

A particular body-mass index;
A particular treatment duration;
A single dosage form;
Simultaneous administration;
A controlled-release formulation;
A specific phentermine/topiramate ratio; or
FDA-approved Qsymia strengths.

Claims 11 through 14 add alternative patient descriptions. Claim 11 covers overweight subjects, claim 12 covers obese subjects, claim 13 covers subjects who are neither overweight nor obese, and claim 14 covers subjects with a condition that can be alleviated by weight loss.

The inclusion of claim 13 materially broadens the population beyond the conventional obesity indication. A product or regimen could fall within the method claims even if administered to a subject who does not meet a conventional overweight or obesity definition, provided the treatment is practiced for the claimed weight-loss objective.

What compounds are covered by the sulfamate derivative language?

The structural language in claim 1 covers an anticonvulsant sulfamate derivative with substituent options that include:

X as CH2 or O;
R1 through R5 independently selected from hydrogen or C1-C4 alkyl;
Methylene dioxy linkages;
Cyclopentyl or cyclohexyl ring options in specified positions.

Claim 2 identifies topiramate as the specifically claimed compound. Topiramate has the relevant sulfamate structure and is the compound commercially used with phentermine in Qsymia.

The practical commercial value of the genus was limited by several factors. Topiramate was already a marketed anticonvulsant, and the patent did not create a new composition-of-matter monopoly over topiramate itself. The patent instead covered the use of topiramate in combination with phentermine for weight loss and the corresponding combination composition.

What do claims 2 through 10 cover for topiramate and phentermine?

Claims 2 through 10 create overlapping dosage fallback positions.

Claim set	Scope
Claim 2	Topiramate plus phentermine for weight loss
Claim 3	Phentermine at 5-60 mg daily
Claim 4	Topiramate at 50-1,500 mg daily
Claim 5	Topiramate below 400 mg daily
Claim 6	Topiramate at 50-400 mg daily
Claim 7	Phentermine at 15 mg daily
Claims 8-10	Claim 7 combined with the topiramate ranges in claims 4-6

The claims overlap substantially. For example, a regimen using 15 mg of phentermine and 100 mg of topiramate would fall within claims 2, 3, 4, 5, 6, 7, 8, 9, and 10, assuming the other limitations are met.

The approved Qsymia strengths use lower topiramate doses than the broad 50-1,500 mg range. Qsymia was approved in four strengths, combining phentermine with extended-release topiramate. The commercial strengths included 3.75/23 mg, 7.5/46 mg, 11.25/69 mg, and 15/92 mg of phentermine/topiramate, respectively (FDA, 2012).

Do the claims require a fixed-dose combination product?

No. The patent expressly covers both single-formulation and separate administration approaches.

Claims 15 and 16 cover simultaneous administration, including administration in a single pharmaceutical formulation. Claims 17 and 18 cover separate administration and different times of day. Claims 19 and 24 specifically describe morning phentermine administration followed by topiramate later in the day.

This distinction was commercially important because the patent reaches beyond a Qsymia-like capsule. A regimen using separate generic phentermine and generic topiramate could have implicated the method claims during the patent term if practiced for the claimed weight-loss purpose and within the other claim limitations.

After expiration, the claims no longer create a live US patent infringement barrier. Separate generic products remain subject to ordinary prescription, labeling, safety, and regulatory requirements.

What does claim 29 protect?

Claim 29 recites:

A pharmaceutical composition comprising topiramate and phentermine.

This is an independent composition claim. Unlike the method claims, it does not expressly require:

Weight loss;
A patient;
A particular dose;
Oral administration;
A specific release profile;
A fixed ratio;
A controlled-release topiramate component; or
FDA-approved Qsymia labeling.

The term “comprising” makes the claim open-ended. A composition containing topiramate and phentermine could include additional excipients, coating materials, release-control polymers, or other components without necessarily falling outside the claim.

The claim’s breadth is constrained by ordinary claim construction, written-description and enablement requirements, and the patent’s specification. It also does not cover topiramate alone, phentermine alone, or every weight-loss product containing a different anticonvulsant.

What formulation and dosing technologies are covered?

Claims 25 through 27 address product-design and regimen features that distinguish the patent from a simple combination claim.

Dose escalation

Claim 25 covers gradually increasing topiramate from an initial daily dose to a final maintenance dose. This limitation corresponds to the clinical practice of titrating topiramate to improve tolerability and manage adverse effects.

Release characteristics

Claim 26 requires phentermine in an immediate-release dosage form. Claim 27 permits topiramate in either immediate-release or controlled-release form.

The claims therefore encompass a product with:

Immediate-release phentermine;
Controlled-release topiramate;
Oral administration; and
A combined or separate dosage presentation.

That combination is closely aligned with the design of Qsymia, although the claims are not limited to the exact Qsymia formulation, strength, capsule architecture, or excipient system.

Timing of administration

The separate-administration claims are broad enough to reach a regimen in which phentermine is taken in the morning and topiramate is taken later in the day. This may have been relevant to product strategies using separate generic tablets rather than a fixed-dose capsule.

When did US Patent 7,659,256 expire?

The patent’s ordinary 20-year term ran from the earliest effective US nonprovisional filing date associated with the patent family. Public patent records identify October 28, 2022, as the relevant expiration date for the patent family, subject to any listed term adjustment or extension (USPTO, n.d.-a).

Event	Date
Patent issued	February 9, 2010
Qsymia FDA approval	July 17, 2012
Ordinary patent expiration	October 28, 2022
Patent status after expiration	No longer an enforceable ordinary US patent right

The expiration date should be distinguished from FDA regulatory exclusivity. FDA marketing exclusivity and patent protection operate independently. Qsymia’s FDA approval did not extend the ordinary patent term. Any pediatric exclusivity, if applicable to a listed product or patent, would have been a separate six-month regulatory or patent-term consideration under the applicable FDA and USPTO records.

What was the Orange Book status of Qsymia?

Qsymia was approved under NDA 022580 for chronic weight management in adults meeting specified BMI and comorbidity criteria. The FDA labeling identified Qsymia as an extended-release combination of phentermine hydrochloride and topiramate (FDA, 2023).

Qsymia’s Orange Book protection involved more than one patent or patent-family member. The principal early patents associated with the combination included:

Patent	General subject matter	Historical relevance
US 7,533,818	Phentermine/topiramate weight-loss methods and compositions	Early Qsymia combination patent
US 7,659,256	Combination methods and topiramate/phentermine composition	Core method and composition coverage
Later continuation or formulation patents	Product, formulation, or related combination coverage	Potentially relevant depending on product and listing date

Orange Book listings must be assessed by NDA, strength, dosage form, and the patent information submitted by the NDA holder. A patent can be listed for a drug product without every claim covering every possible generic design. Conversely, a generic applicant must evaluate all unexpired listed patents relevant to the proposed product, not only US 7,659,256.

Were there Paragraph IV challenges to Qsymia patents?

Generic applicants seeking approval before expiration of listed patents could use an ANDA with a Paragraph IV certification. That certification would assert that a listed patent is invalid, unenforceable, or not infringed.

Public company disclosures and litigation reporting indicate that VIVUS faced generic challenges involving Qsymia patent rights, including litigation against generic drug manufacturers concerning ANDA filings. These disputes centered on the listed Qsymia patent estate, including patents covering the phentermine/topiramate combination and related formulations. Settlement terms in branded-drug patent cases can establish an agreed generic-entry date without resolving validity through a final court judgment (VIVUS, Inc., 2014).

The commercial impact of a Paragraph IV case against US 7,659,256 would have depended on:

Whether the ANDA product contained both active ingredients;
Whether the product used the claimed release profile;
Whether the proposed labeling induced the claimed weight-loss use;
Whether the applicant pursued a section viii carve-out;
Whether the patent remained unexpired at the time of launch; and
Whether other Qsymia patents remained enforceable.

Because US 7,659,256 expired in 2022, a new Paragraph IV challenge against this patent alone no longer provides a route to earlier entry. A current generic applicant would focus on any unexpired listed patents, regulatory exclusivity, controlled-substance requirements, and product-specific formulation rights.

What litigation affected US Patent 7,659,256?

The patent was part of the Qsymia patent enforcement environment involving ANDA filers and generic-entry disputes. The relevant legal issues would have included:

Direct infringement of composition claim 29;
Induced infringement of method claims through proposed labeling;
Infringement under the doctrine of equivalents;
Anticipation and obviousness based on prior phentermine/topiramate studies;
Written-description and enablement challenges to the broad sulfamate genus;
Claim construction concerning “therapeutically effective amount”; and
Whether the generic product’s labeling encouraged the claimed weight-loss regimen.

A final litigation assessment requires separating case-specific outcomes from the patent’s claim text. The broadest claims were potentially vulnerable to prior-art and obviousness arguments because phentermine and topiramate were each known drugs, and combination treatment could be challenged as an obvious therapeutic combination. The patent’s commercial strength derived from the claimed weight-loss use, dosing, timing, titration, and product configuration rather than from novelty of either active ingredient individually.

How strong was the patent estate for Qsymia?

Historically, the estate had moderate commercial strength but limited long-term exclusivity value.

Factor	Assessment
Active ingredients	Weak composition-of-matter position because both ingredients were known
Combination use	Stronger, because the claimed indication was weight loss
Genus claim	Broad but exposed to validity and enablement arguments
Qsymia-specific formulation	More defensible if supported by separate formulation patents
Method-of-use coverage	Potentially important against labeled ANDA products
Regulatory exclusivity	Temporary and separate from patent rights
Current enforceability	None for an expired US 7,659,256 patent
Generic substitution risk	High after patent expiration, subject to formulation and regulatory barriers

The most valuable claims during the patent term were claims 2, 6, 7, 10, 20, 21, 24, 25, 27, and 29. Together, they mapped onto the commercial product and common alternative administration patterns.

How does the patent compare with generic-entry risks today?

The main barriers to a generic phentermine/topiramate product are no longer the expired claims of US 7,659,256. Current barriers can include:

Unexpired patents listed for the specific NDA;
Formulation or controlled-release patents;
Manufacturing know-how involving topiramate release control;
ANDA requirements for bioequivalence;
Controlled-substance handling for phentermine;
Risk Evaluation and Mitigation Strategy obligations, if applicable;
Labeling restrictions;
Distribution controls; and
Commercial difficulty in matching Qsymia’s titration and safety-label requirements.

No biosimilar pathway applies. Qsymia is a small-molecule combination product, so a competing product would generally use the ANDA pathway or, depending on its formulation and clinical strategy, an NDA pathway. Biosimilar litigation concepts under the Biologics Price Competition and Innovation Act are not relevant.

What manufacturing and intellectual-property barriers remain?

The active ingredients themselves are available from established generic sources. The more difficult technical issue is reproducing the desired pharmacokinetic profile of a combined product, particularly when phentermine is immediate release and topiramate is extended release.

Manufacturing and development barriers can include:

Particle-size and solid-state control;
Uniform distribution of low-dose phentermine;
Controlled-release coating or matrix design for topiramate;
Dose proportionality across strengths;
Dissolution-profile matching;
Stability of the combined dosage form;
Capsule filling and content uniformity;
Bioequivalence across multiple strengths; and
Labeling for dose escalation and discontinuation.

These barriers can affect market entry even when the core patent has expired. They do not, however, restore exclusivity to US 7,659,256.

What generic launch scenarios exist for phentermine/topiramate?

Three principal scenarios apply:

Separate generic products. Generic phentermine and generic topiramate can be prescribed separately, but the physician and patient bear responsibility for dosing, timing, titration, and adherence.
Generic fixed-dose combination. An ANDA applicant may seek approval for a Qsymia-equivalent combination product, subject to Orange Book review, bioequivalence, controlled-substance requirements, and any surviving patents.
Alternative combination formulation. A manufacturer may develop a different release profile or strength strategy, reducing exposure to formulation-specific claims but potentially requiring additional clinical or regulatory support.

The expiration of US 7,659,256 materially reduces the legal risk for all three models. The commercial opportunity depends on whether the generic product can achieve a reliable, economical, and regulatorily acceptable replacement for Qsymia.

Key Takeaways

US 7,659,256 covered phentermine combined with a sulfamate anticonvulsant, with topiramate as the principal commercial embodiment.
Claim 1 was a broad combination weight-loss method claim.
Claim 2 narrowed the invention to topiramate plus phentermine.
Claims 15 through 24 covered simultaneous and separate administration, including morning phentermine and later-day topiramate.
Claims 25 through 27 covered titration and immediate-release or controlled-release dosage forms.
Claim 29 broadly covered a pharmaceutical composition comprising topiramate and phentermine.
The patent did not create a new chemical monopoly over phentermine or topiramate individually.
The patent’s ordinary term expired on October 28, 2022.
Qsymia had separate FDA exclusivity and additional patent-family considerations.
No biosimilar pathway applies because Qsymia is a small-molecule combination product.
Current generic risk depends mainly on other unexpired patents, product-specific formulation rights, regulatory requirements, and manufacturing execution.

FAQs About US Patent 7,659,256 and Qsymia

Can a company now market phentermine and topiramate together in the United States?

The expiration of US 7,659,256 removes that patent as a current infringement barrier. The product must still satisfy FDA approval, labeling, controlled-substance, manufacturing, and any other unexpired patent requirements.

Did US Patent 7,659,256 cover generic phentermine by itself?

No. The claims require phentermine in combination with a qualifying sulfamate anticonvulsant, or specifically with topiramate in the narrower claims.

Did US Patent 7,659,256 cover topiramate for epilepsy?

No. The claimed use is the administration of phentermine and a sulfamate anticonvulsant to effect weight loss. Topiramate monotherapy for epilepsy is outside the claimed combination.

Could a generic use separate phentermine and topiramate tablets?

During the patent term, separate administration could have implicated claims 17 through 24. After expiration, those claims no longer impose an enforceable US patent restriction.

Is Qsymia protected by a biologic patent or biosimilar exclusivity?

No. Qsymia is a small-molecule drug combination. Generic competition is addressed through the ANDA framework rather than the biosimilar pathway.

What is the principal remaining risk for a generic Qsymia product?

The principal risks are other unexpired Orange Book patents, formulation-specific rights, FDA approval requirements, controlled-substance compliance, and the need to demonstrate bioequivalence for the release profile and approved strengths.

References

Food and Drug Administration. (2012). FDA approves weight-management drug Qsymia. U.S. Department of Health and Human Services.
Food and Drug Administration. (2023). Qsymia prescribing information. U.S. Department of Health and Human Services.
U.S. Patent and Trademark Office. (n.d.-a). Patent no. 7,659,256, patent term and bibliographic records. U.S. Department of Commerce.
U.S. Patent and Trademark Office. (n.d.-b). Orange Book patent listing and patent-term resources. U.S. Department of Commerce.
VIVUS, Inc. (2014). Annual report and public disclosures concerning Qsymia patent litigation and generic challenges. VIVUS, Inc.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	369126	⤷ Start Trial
Australia	2008262566	⤷ Start Trial
Australia	5489600	⤷ Start Trial
Australia	770068	⤷ Start Trial
Canada	2377330	⤷ Start Trial
Canada	2686633	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,659,256

Summary for Patent: 7,659,256